Showing 111-120 of 179 results for "".
Recent Developments
https://practicaldermatology.com/columns/recent-developments/recent-developments-3/23049/Recent Developments
https://practicaldermatology.com/columns/recent-developments/recent-developments/20748/The HRQoL Impact of Psoriasis: Perspectives for Value-Based Reimbursement
https://practicaldermatology.com/topics/psoriasis/the-hrqol-impact-of-psoriasis-perspectives-for-value-based-reimbursement/20932/Understanding the psychological/social burden of psoriasis on patients is critical as new therapeutics position themselves for reimbursement in a crowded and increasingly undifferentiated field.Real-Life Treatment Strategies: Topical Combination Therapy for Plaque Psoriasis in Patients With Skin of Color
https://practicaldermatology.com/topics/psoriasis/real-life-treatment-strategies-topical-combination-therapy-for-plaque-psoriasis-in-patients-with-skin-of-color/21213/Management of psoriasis among individuals with skin of color will become increasingly important for medical professionals. Here's a review of the distinguishing features of psoriasis in patients with skin of color and their treatment needs.Recent Developments
https://practicaldermatology.com/columns/recent-developments/recent-developments/21709/Therapeutic Review: A Host of New Treatments Emerged in 2018
https://practicaldermatology.com/topics/psoriasis/therapeutic-review-a-host-of-new-treatments-emerged-in-2018/20381/Here's a handy reference to new drugs and devices—and other key developments—this year.Psychodermatology: A Review
https://practicaldermatology.com/topics/practice-management/psychodermatology-a-review/21180/Recent Developments
https://practicaldermatology.com/columns/recent-developments/news/20326/Advanced Management Solutions for High-Grade Cutaneous Toxicities to Cancer Therapy
https://practicaldermatology.com/topics/skin-cancer-photoprotection/advanced-management-solutions-for-high-grade-cutaneous-toxicities-to-cancer-therapy/57176/The emergence of immune checkpoint inhibitors (ICIs) has fundamentally altered the prognosis for patients with advanced skin malignancies, yet the high incidence of cutaneous immune-related adverse events (irAEs) remains a significant barrier to treatment continuity. Here, we review the clinical man2022 in Review
https://practicaldermatology.com/topics/other-dermatology/2022-in-review/23833/The past year brought many new approvals and advances to dermatology for improved patient care.